Texas Tech University researchers have identified a possible therapeutic target, the enzyme JNK3, for spinal muscular atrophy (SMA) that is independent of the causing genetic mutation. Their research, titled “Genetic Inhibition of JNK3 Ameliorates ...
By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.